GANSID Congress 2026 Program

Abstract Presentation Hall 1

Abstract Presentation Hall 2

Abstract Presentation Room 6

Local Trainees and Fellows’ Abstract Presentations

GANSID Mentorship Program: Two Years of Advancing Clinician Capacity Building

• Reflections from a GANSID Mentor & Mentee

Advances in Thrombosis Management: From Anticoagulation to Emerging Targeted Therapies

• Current anticoagulation strategies and clinical challenges (including real-world implementation and special populations)
• Emerging targeted therapies (e.g., factor XI/XIa inhibitors, novel pathways)

Glucose-6-Phosphate Dehydrogenase Deficiency

• Advances in Screening, Diagnosis, and Risk Stratification
• Drug-Induced Haemolysis in G6PD Deficiency

Hereditary Hemorrhagic Telangiectasia: Advances in Diagnosis, Management, and Systemic Therapies

• Diagnosis and Multidisciplinary Management of HHT: Current Evidence and Global Standards

Understanding Health Risks in Hemoglobinopathies and Bleeding Disorders Trait

• Genetic Counselling and Family Planning in Hemoglobinopathy Traits
• Health Risks and Clinical Implications of Sickle Cell Trait
• Patient Organizations' Role in Reducing Unplanned Bleeding Disorders Births

Comprehensive Approaches to Iron Overload Prevention in Thalassemia

• Clinical Impact of Ineffective Erythropoiesis & Anemia
• Stepwise Laboratory Evaluation of Thalassemia
• Iron Toxicity in Thalassemia: Key Concepts in Iron Overload Management

Diagnostic Pitfalls in Mild and Atypical Hereditary Spherocytosis & Red Cell Membrane Disorder

• Modern Diagnostic Approaches to Hereditary Spherocytosis and Overlapping Membrane Disorders
• Atypical and Mild Presentations of Red Cell Membrane Disorders: Avoiding Misdiagnosis in Clinical Practice

Legal Issues in Medical Practice - Current Perspectives

Africa CDC Continental Plan on Sickle Cell Disease and Other Inherited Blood Disorders

Abstract Presentation Hall 1

Abstract Presentation Hall 2

Abstract Presentation Room 6

Industry Symposia: Novo Nordisk

Inclusive Clinical Trials for Global Impact: The Role of GANSID in Driving Change

• Designing Inclusive Clinical Trials in Rare Hematological Disorders: From Eligibility Criteria to Real-World Representation
• Global Equity in Hematology Trials: Bridging Gaps in Access, Participation, and Impact

Von Willebrand Disease in the 21st Century

• VWD: The Global Challenge
• Integrating Molecular Science with Clinical Care

Hematopoietic Stem Cell Transplantation in Aplastic Anemia

• HSCT in Aplastic Anemia: Patient Selection, Timing & Outcomes
• Evolving Indications & Outcomes in Aplastic Transplantation

Pipeline Therapies for Inherited Blood Disorders

• Pipeline Therapies: What Is the Need?
• Investigational Therapies for SCD & Thalassemia
• Investigational Therapies for Inherited Bleeding Disorders

Patient-Driven Session: Expanding Access to Innovative & Curative Therapies in Inherited Blood Disorders (IBDs) within the WHO Universal Health Care Framework

• Patient Experiences with Innovative and Curative Therapies Across Health Systems
• From Advocacy to Policy: Leveraging the WHO Universal Health Care Framework to Drive Equitable Access for Sickle Cell Communities
• Building Comprehensive Thalassemia Care Within National Health Systems

Redefining Diagnosis & Management in Inherited Thrombocytopenia

• Recognizing Inherited Thrombocytopenia: Diagnosis, Clinical Clues & First-Line Lab Tests
• Management Essentials: When to Treat, When to Refer & Avoiding Common Pitfalls

Inflammation & Complement Activation: Mechanistic Drivers of Disease Severity in SCD

• Inflammation & Complement in SCD: Drivers of Vaso-Occlusion & Organ Damage
• Genetic Modifiers of the SCD Phenotype

Disparities in Access to Lifelong Care for Thalassemia: A Global Lens

• Bridging Gaps in Access to Diagnosis, Transfusion & Treatment Across High- & Low-Resource Settings
• Resolving System-Level Barriers to Continuity of Care

Abstract Presentation Hall 1

Abstract Presentation Hall 2

Abstract Presentation Room 6

Local Trainees and Fellows’ Abstract Presentations

Clinical & Operational Challenges in Blood Safety: Balancing Demand, Supply & Patient Outcomes

• Hemovigilance & Transfusion Safety: From Adverse Event Reporting to Quality Improvement
• Blood Supply Shortfalls in Low- and Middle-Income Countries: Structural Barriers & Pragmatic Solutions

Targeted Therapy in Pyruvate Kinase Deficiency (PKD): PK Activators & Beyond

• Genetic therapies in PKD: the platinum standard, but even rarer.
• PK activators, their function, and impact

Bone Marrow Failure Syndromes: From Molecular Pathogenesis to Curative Strategies

• Key Molecular Mechanisms Underlying Bone Marrow Failure Syndromes
• From Diagnosis to Cure: Management & Curative Options Including Transplant & Emerging Therapies

Emerging & Long-Term Toxicities of Gene & Cell Therapies: What Clinicians Need to Know

• Early & Delayed Toxicities: Identifying, Monitoring & Managing Adverse Effects
• Safety, Surveillance & Risk Mitigation: Long-Term Follow-Up & Registries

Advancing Social Justice & Human Rights in Inherited Blood Disorders: Addressing Work, Disability & Social Participation

• From Policy to Impact: Building Centres of Competence and Comprehensive Rehabilitation for Inherited Blood Disorders.
• Social Justice Framework: Rights, Recognition, and Representation in IBD
• Beyond the Disease: Social Participation, Community Belonging, and Quality of Life in IBD Communities